AAAAAA

   
Results: 1-8 |
Results: 8
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
Authors: Akkerhuis, KM van den Brand, MJBM van der Zwaan, C Peels, HOJ Suryapranata, H van der Wieken, LR Stibbe, J Hoffmann, J Baardman, T Deckers, JW Simoons, ML
Citation: Km. Akkerhuis et al., Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty, HEART, 85(4), 2001, pp. 444-450
Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events - Meta-analysis of three studies involving 995 patients
Authors: Akkerhuis, KM Klootwijk, PAJ Lindeboom, W Umans, VAWM Meij, S Kint, PP Simoons, ML
Citation: Km. Akkerhuis et al., Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events - Meta-analysis of three studies involving 995 patients, EUR HEART J, 22(21), 2001, pp. 1997-2006
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention
Authors: Akkerhuis, KM Deckers, JW Lincoff, AM Tcheng, JE Boersma, E Anderson, K Balog, C Califf, RM Topol, EJ Simoons, ML
Citation: Km. Akkerhuis et al., Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention, J AM MED A, 286(1), 2001, pp. 78-82
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT
Authors: Akkerhuis, KM Deckers, JW Boersma, E Harrington, RA Stepinska, J Mahaffey, KW Wilcox, RG Lincoff, AM Keltai, M Topol, EJ Califf, RM Simoons, ML
Citation: Km. Akkerhuis et al., Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT, EUR HEART J, 21(5), 2000, pp. 371-381
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation - A phase II study
Authors: Akkerhuis, KM Neuhaus, KL Wilcox, RG Vahanian, A Boland, JL Hoffmann, J Baardman, T Nehmiz, G Roth, U Klootwijk, APJ Deckers, JW Simoons, ML
Citation: Km. Akkerhuis et al., Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation - A phase II study, EUR HEART J, 21(24), 2000, pp. 2042-2055
Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: Relation with death and myocardial infarction
Authors: Akkerhuis, KM Maas, ACP Klootwijk, PAJ Krucoff, MW Meij, S Califf, RM Simoons, ML
Citation: Km. Akkerhuis et al., Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: Relation with death and myocardial infarction, J ELCARDIOL, 33(2), 2000, pp. 127-136
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients
Authors: Boersma, E Pieper, KS Steyerberg, EW Wilcox, RG Chang, WC Lee, KL Akkerhuis, KM Harrington, RA Deckers, JW Armstrong, PW Lincoff, AM Califf, RM Topol, EJ Simoons, ML
Citation: E. Boersma et al., Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients, CIRCULATION, 101(22), 2000, pp. 2557-2567
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes - Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
Authors: Boersma, E Akkerhuis, KM Theroux, P Califf, RM Topol, EJ Simoons, ML
Citation: E. Boersma et al., Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes - Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention, CIRCULATION, 100(20), 1999, pp. 2045-2048
Risultati: 1-8 |